Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Trading 11-02 09:40:34 EST

30.99

-0.49

-1.56%

High31.70	Low30.41	Vol12.31K
Open31.70	D1 Closing31.48	Amplitude4.10%
Mkt Cap1.71B	Tradable Cap1.15B	Total Shares55.25M
T/O384.79K	T/O Rate0.03%	Tradable Shares37.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":30.99,"timestamp":1793630401420,"preClose":31.48,"halted":0,"volume":12305,"delay":0,"changeRate":-0.015565438373570583,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Trading","change":-0.49,"latestTime":"11-02 09:40:34 EST","open":31.7,"high":31.7,"low":30.41,"amount":384791.390005,"amplitude":0.040978,"askPrice":31.35,"askSize":4,"bidPrice":30.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793653200000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":31.48,"preHourTrading":{"tag":"盘前","latestPrice":31.48,"preClose":31.48,"latestTime":"08:24 EST","volume":2312,"amount":72781.76,"timestamp":1793625851451,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":30.59,"preClose":31.48,"latestTime":"19:30 EDT","volume":20273,"amount":640396.6703,"timestamp":1793403002435,"change":-0.89,"changeRate":-0.028272,"amplitude":0.051144},"volumeRatio":0.995922,"impliedVol":1.0725,"impliedVolPercentile":0.7092},"requestUrl":"/m/hq/s/MAZE/tweets","defaultTab":"tweets","newsList":[{"id":"2679247443","title":"Maze Therapeutics CSBO Atul Dandekar Reports Sale of Common Shares Worth $240,531.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2679247443","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679247443?lang=en_us&edition=fundamental","pubTime":"2026-10-31 04:15","pubTimestamp":1793391334,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar Reports Sale of Common Shares Worth $240,531.75Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on October 29, 2026, at a weighted-average price of $3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nNDL1t5CvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Reports Sale of Common Shares Worth $240,531.75","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677160891","title":"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677160891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677160891?lang=en_us&edition=fundamental","pubTime":"2026-10-21 22:50","pubTimestamp":1792594210,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ionis-pharmaceuticals-ions-maze-therapeutics-inc-maze-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ionis-pharmaceuticals-ions-maze-therapeutics-inc-maze-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IHI","LU0128526141.USD","IE0002141913.USD","LU1023059063.AUD","LU1721429741.USD","HCSG","LABU","LU1721429402.USD","LU2211815571.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0868494617.USD","LU2237957902.USD","IE0009355771.USD","LU0266013472.USD","PJP","SG9999002232.USD","LU0208291251.USD","LU0058720904.USD","LU0114720955.EUR","LU2324357040.USD","IONS","MAZE","TMED","LU0234572021.USD","IE00BFTCPJ56.SGD","LU1670628061.USD","LU0170899867.USD","LU2133065610.SGD","LU2237957811.SGD","LU1914381329.SGD","LU1670627923.USD","XLV","BK4585","BK4504","XBI","LU0070302665.USD","LU0320765489.SGD","ABT","IE00B4R5TH58.HKD","BK4533","LU1983299246.USD","LU1989763690.USD","BK4592","LU1691799644.USD","BK4139","IE00BJT1NW94.SGD","BK4007","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676689724","title":"Maze Therapeutics, Inc. : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2676689724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676689724?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:37","pubTimestamp":1792417030,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nFWN46511Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676685429","title":"Maze Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2676685429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676685429?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:26","pubTimestamp":1792412760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676504259","title":"Maze Therapeutics initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2676504259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676504259?lang=en_us&edition=fundamental","pubTime":"2026-10-19 17:41","pubTimestamp":1792402887,"startTime":"0","endTime":"0","summary":"Canaccord initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $75 price target The company’s lead asset MZE829 is an oral small mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676937511","title":"Maze Therapeutics Exchanges 2,776,007 Common Shares for Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2676937511","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676937511?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:06","pubTimestamp":1792181165,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Exchanges 2,776,007 Common Shares for Pre-Funded WarrantsMaze Therapeutics exchanged 2,776,007 common shares held by Frazier Life Sciences funds for pre-funded warrants on October 15","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDLBQRLm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675584313","title":"Maze Therapeutics, Inc. (MAZE) Gets a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2675584313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675584313?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:58","pubTimestamp":1792065502,"startTime":"0","endTime":"0","summary":"In a report released today, Sadia Rahman from Wells Fargo maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $55.00. Rahman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310799852.SGD","LU0971096721.USD","LU0149725797.USD","LU0251142724.SGD","LU0267386448.USD","LU0052756011.USD","LU0128525929.USD","LU1267930490.SGD","LU1894683264.USD","LU0417517546.SGD","LU1791807156.HKD","LU0942090050.USD","BK4559","LU0868494617.USD","BK4585","IE00B19Z3B42.SGD","LU1267930573.SGD","LU2461242641.AUD","PGF","IE000M9KFDE8.USD","LU0029864427.USD","MAZE","FTXO","BK4207","LU0256863811.USD","LU1267930227.SGD","LU1894683348.USD","LU0314106906.USD","LU1814569148.SGD","LU0320765489.SGD","LU0310800965.SGD","IE0002270589.USD","LU1201861249.SGD","LU1668664300.SGD","LU0787776722.HKD","LU0640476718.USD","LU0106831901.USD","LU0868494708.USD","LU0980610538.SGD","LU1074936037.SGD","LU0683600562.USD","BK4582","BK4504","LU0072461881.USD","IYF","BK4501","LU1035773651.USD","TFNS","IE00B19Z3581.USD","KBWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063956","title":"Maze Therapeutics to Present Phase 2 Horizon Data for Mze829 in APOL1-Mediated Kidney Disease at ASN Kidney Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063956?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:07","pubTimestamp":1791317269,"startTime":"0","endTime":"0","summary":"Maze Therapeutics to present Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease at ASN Kidney Week 2026Maze Therapeutics flagged upcoming presentations on its kidney pipeline at ASN Kidn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL5d8pBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BCDF","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","IE00BQXX3C00.GBP","BK4007","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00BN0W2T93.GBP","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4588","MAZE","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672764185","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2672764185","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672764185?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:07","pubTimestamp":1790885254,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75Maze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 shares at USD 10.42 on Sept. 29, 2026.He so","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL40cPjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488852","title":"Maze Therapeutics Rises After Citi Initiates with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488852?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:16","pubTimestamp":1790162183,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises after Citi initiates with 'buy'** Shares of biotech firm Maze TherapeuticsMAZE.Orise 1.5% to $28.8 premarket** Brokerage Citi initiates coverage with \"buy\" and a $50 PT, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104282","title":"Maze Therapeutics initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669104282?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:20","pubTimestamp":1790155214,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $50 price target The firm sees the company’s APOL1-mediated kidney diseas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669712668","title":"Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669712668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669712668?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:50","pubTimestamp":1790095800,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc.  is currently at $27.23, up $4.84 or 21.62%--Would be highest close since Aug. 28, 2026, when it closed at $27.44--On pace for largest percent increase since Sept. 11, 2025, when it rose 54.81%--Snaps a five day losing streak--Up 2.48% month-to-date--Down 34.27% year-to-date--Down 47.47% from its all-time closing high of $51.84 on March 12, 2026--Up 9.45% from 52 weeks ago , when it closed at $24.88--Down 47.47% from its 52-week closing high of $51.84 on March 12, 2026--Up 21.62% from its 52-week closing low of $22.39 on Sept. 21, 2026--Traded as high as $29.40; highest intraday level since Aug. 26, 2026, when it hit $30.40--Up 31.31% at today's intraday high; largest intraday percent increase since Sept. 11, 2025, when it rose as much as 59.18%All data as of 12:44:05 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","MAZE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERX","LU2089984988.USD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","LU1559883803.SGD","IE00B19Z3581.USD","XBI","IE00B2B36J28.USD","LU1778281490.HKD","LU2362541513.USD","LU1035775433.USD","MAZE","LU1093756168.USD","BK4023","LU0889565916.HKD","BBH","TBXU","LU2462157665.USD","IBBQ","BK4585","LU2324357040.USD","IDNA","PBE","GNMX","IE0009355771.USD","IE00B894F039.SGD","LU1430594728.SGD","VRTX","LU0079474960.USD","LU1815336091.USD","LU2237438978.USD","LU1585245621.USD","IE00BZ9MQY76.HKD","LU2456880835.USD","LU0256863811.USD","LU1069344957.HKD","LU0432979614.USD","IBB","IE0002141913.USD","BK4567","BIB","BK4532","SGXZ57979304.SGD","LU2236285917.USD","LU0289739699.SGD","BK4588","LU0234570918.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377654","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377654","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377654?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:21","pubTimestamp":1788898887,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of 9,705 common shares for $254,543Harold Bernstein, President, R&D & CMO, sold 9,705 shares of Maze Therapeutics common stock on Sep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3v02SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664801180","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2664801180","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664801180?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:24","pubTimestamp":1788467093,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein sells 16,141 common shares worth $425,392.65Harold Bernstein, President, R&D & CMO, reported a same-day exercise and sale in Maze Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL66dvcM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815092","title":"Maze Therapeutics to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815092","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815092?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354981/0/en/maze-therapeutics-to-participate-in-three-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885024","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885024","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885024?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:33","pubTimestamp":1788215589,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $206,823.75Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on Aug. 28, 2026 at USD 27.58.The sale followed the exerci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLJqTrc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778685","title":"Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778685?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:33","pubTimestamp":1787808780,"startTime":"0","endTime":"0","summary":"GENEVA, Aug. 27, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA  , a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update.Key Highlights-- Expanded U.S. commercial capabilities and reach through the build-out of. the Company's commercial organization, continued development of its. customer pipeline, and a channel partnership with Vibra Healthcare.-- Compelling real-world evidence from a two-year, multi-site program. -- Advanced its European reimbursement strategy with first patient. enrollment in SwissNeuroRehab and launch of the REACT-AVC study in. -- Expanded the clinical application of the platform through support for a. University of Pittsburgh study pairing spinal cord stimulation with. -- Completed organizational simplification, including the disposal of. non-neurology legacy operations, resulting in a focused organization and. -- Received CHF 4.0 million under a CHF 8.0 million ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660324524","title":"Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660324524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660324524?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:46","pubTimestamp":1786999574,"startTime":"0","endTime":"0","summary":"Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statementMaze Therapeutics director Paula A. Johnson filed an initial Form 3 on Aug. 17, 2026.Disclaimer:This news brief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL78z2DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328084","title":"Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328084","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660328084?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:18","pubTimestamp":1786997890,"startTime":"0","endTime":"0","summary":"Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directorsMaze Therapeutics named Paula Johnson and Sophie Kornowski to its board of directors.Johnson is president of Wellesley Coll","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL87kkJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":0.1582},{"period":"3month","weight":0.1694},{"period":"6month","weight":0.1586},{"period":"1year","weight":-0.0524},{"period":"ytd","weight":-0.2402}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction